• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Gorodeski to Unveil Role of P2X7 in Endometrial Cancer Prevention & Treatment at Onco-Molecular Diagnostics Conference in San Francisco

Posted on: Thursday, 24 May 2007, 09:00 CDT

Dr. George Gorodeski, Chief Scientist at CytoCore (OTCBB:CYCR), will present new aspects of his pioneering research that reveal the ability of the P2X7 receptor to screen uterine cancer and its implications for therapeutics and prevention at the Onco-Molecular Diagnostics Conference in San Francisco, June 7-8, 2007.

Dr. Gorodeski's work on the role of the breakthrough P2X7 protein receptor in epithelial cells began in 1989 at a time when most researchers in the field were occupied with the P2X7 in immune system cells. Recent efforts in Gorodeski's lab at University Hospitals Case Medical Center (UHCMC) have yielded new data now undergoing clinical testing.

Dr. Gorodeski's presentation at the Conference will cover four aspects of the recent discoveries, including the physiological and patho-biological role of P2X7 in epithelial cells; the potential role of P2X7 as a cancer biomarker; the post-transcriptional control of P2X7 expression; and the therapeutic and cancer prevention potential of treatments targeting up-regulation of P2X7-mediated apoptosis.

"Dr. Gorodeski's studies in human uterine epithelial cells have led to significant discoveries of the P2X7 signaling its role in cancer development. Of special interest in these new findings is the P2X7's potential as a therapeutic treatment compound," said Richard Domanik, CytoCore's President. "Initially, CytoCore intends to utilize the P2X7 biomarker in an endometrial cancer screening test that can detect uterine cancer earlier, more accurately and more comfortably than a conventional biopsy. We have an investigator-blinded study currently working to validate the accuracy of the P2X7 as an epithelial cancer biomarker of the endometrium. We are also engaged in efforts to develop novel pharmacological cancer treatments utilizing the P2X7 mechanism. When combined with the P2X7's capability for early detection of cancer -- currently being tested in a clinical trial -- having the potential to provide an effective cancer therapeutic from the same gene could be very beneficial."

About the Conference

Washington G-2 Reports' Onco-Molecular Diagnostics Conference, From Bench to Bedside: Onco-Molecular Diagnostics in the Clinical Laboratory is designed to address practical implications of the growth of oncology-driven molecular diagnostics and gives the needed information to utilize this novel science. http://www.g2reports.com/conferences/777.html

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath™ System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.

Dr. Gorodeski, MD, PhD, Professor of Reproductive Biology, Oncology and Physiology and Bio-physics at Case Western Reserve University and a faculty member at University Hospital Case Medical Center of Cleveland is director of the Medical Advisory Board and Chief Scientist at CytoCore Inc., the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers.

Dr. Gorodeski has a significant financial interest in this research consisting of equity and fees as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore could generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland, and for CASE University.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Source: Business Wire

More News in this Category